Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Cardiovascular adverse effects during itraconazole therapy

S-L. Fung, C-H. Chau, W-W. Yew
European Respiratory Journal 2008 32: 240; DOI: 10.1183/09031936.00021208
S-L. Fung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C-H. Chau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W-W. Yew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

Itraconazole has been widely used in the treatment of fungal disease including chronic necrotising pulmonary aspergillosis (CNPA) 1, 2. Its use has been associated with occasional reports of adverse cardiovascular events including congestive heart failure 3, hypertension (HT) 4, premature ventricular contractions 5 and even ventricular fibrillation 6. However, these adverse effects have been considered to be uncommon, if not rare, occurrences. From September, 1992 to April, 2001, the US Food and Drug Administration received only 59 reports of potential cases of congestive heart failure with the administration of itraconazole 3. Despite the recommendation that itraconazole should not be used for treatment of onychomycosis in patients with evidence of ventricular dysfunction and that monitoring of symptoms and signs of heart failure is required during itraconazole therapy, the association of itraconazole and heart failure is still considered to be controversial 7.

From January, 2005 to December, 2007, seven patients were diagnosed to have CNPA in our institution. Adverse cardiovascular events were found in three patients and suspected in one after the commencement of itraconazole therapy for a variable period of 3 weeks to 4 months. All patients were administered 400 mg of itraconazole, daily. The first patient was a 58-yr-old male who developed congestive heart failure after receiving 3 weeks of itraconazole therapy. He had underlying diabetes mellitus (DM), HT and old tuberculosis (TB). He improved with diuretic therapy and itraconazole was withheld. The second patient was a 71-yr-old male with old TB, DM (with nephropathy, baseline creatinine of ∼400 μmol·L−1) and HT who presented again 10 weeks later with congestive cardiac failure and acute on chronic renal failure. Itraconazole therapy was stopped. His condition improved with diuretic therapy with the serum creatinine level returning to baseline. The third patient was a 55-yr-old male with unremarkable past health and normal baseline blood pressure of 110/70 mmHg. His blood pressure elevated to 160/90 mmHg after 3 months of itraconazole therapy. Other secondary causes of HT could not be identified. He was put on anti-HT therapy and itraconazole was continued. The last subject was a 60-yr-old male who had underlying silicosis and old TB. His blood pressure after commencement of itraconazole was found to be elevated from baseline of 100/70 mmHg to 120/80 mmHg. He was put on observation and itraconazole therapy was continued. He died at home 15 weeks after commencement of itraconazole, 2 days after the last medical follow-up.

Our experience alerted us that the adverse cardiovascular events associated with itraconazole were not an uncommon occurrence. At least three of our seven subjects developed either congestive heart failure or hypertension while receiving 400 mg itraconazole, daily. The exact cause of the sudden death of the fourth patient was uncertain but we suspected major cardiac arrhythmia was the culprit. Patients with underlying risk factors, such as diabetes mellitus or hypertension, were probably more vulnerable to the cardiovascular adverse effects of itraconazole. We suggested that thorough cardiac assessment should be considered in all patients starting on itraconazole. Baseline echocardiogram might be indicated in patients with underlying diabetes mellitus or hypertension and close monitoring of blood pressure is mandatory during therapy.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997;112:541–548.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Wong PC, Fung SL, Lee J, Wong CF, Chau CH, Yew WW. Chronic necrotizing pulmonary aspergillosis: a report of 9 cases with analysis of clinical picture, risk factors and treatment for outcome correlation. Monaldi Arch Chest Dis 2001;56:202–207.
      OpenUrlPubMed
    3. ↵
      Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766–1767.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707–713.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Okamoto J, Fukunami M, Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J 2007;71:1323–1325.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Nelson MR, Smith D, Erskine D, Gazzard BG. Ventricular fibrillation secondary to itraconazole induced hypokalaemia. J Infect 1993;26:348
      OpenUrlPubMedWeb of Science
    7. ↵
      Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf 2006;29:567–586.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 32 Issue 1 Table of Contents
    European Respiratory Journal: 32 (1)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Cardiovascular adverse effects during itraconazole therapy
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Cardiovascular adverse effects during itraconazole therapy
    S-L. Fung, C-H. Chau, W-W. Yew
    European Respiratory Journal Jul 2008, 32 (1) 240; DOI: 10.1183/09031936.00021208

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Cardiovascular adverse effects during itraconazole therapy
    S-L. Fung, C-H. Chau, W-W. Yew
    European Respiratory Journal Jul 2008, 32 (1) 240; DOI: 10.1183/09031936.00021208
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    • Optimised surveillance of bronchial dysplasia in risky population
    • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society